These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 10782563)

  • 1. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis.
    Turk Z; Mrzljak V; Turk N; Metelko Z
    Diabetes Nutr Metab; 1999 Dec; 12(6):413-7. PubMed ID: 10782563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
    McDowell A; Young IS; Wisdom GB
    J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of metabolic control on oxidized low-density lipoprotein antibodies in children and adolescents with type 1 diabetes mellitus.
    Kara C; Cetinkaya S; Sezgin N; Kinik ST
    Pediatr Diabetes; 2008 Feb; 9(1):17-22. PubMed ID: 18211632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
    Cofan F; Cofan M; Campos B; Guerra R; Campistol JM; Oppenheimer F
    Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies against oxidized LDL are associated with severe chest pain attacks in patients with coronary heart disease.
    Luoma JS; Kareinen A; Närvänen O; Viitanen L; Laakso M; Ylä-Herttuala S
    Free Radic Biol Med; 2005 Dec; 39(12):1660-5. PubMed ID: 16298691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis.
    Hequet O; Le QH; Rigal D; Mekhloufi F; Jaeger S; Sassolas A; Groisne L; Moulin P
    Transfus Apher Sci; 2010 Feb; 42(1):3-10. PubMed ID: 19932056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Auto antibodies against oxidized low density lipoprotein in severe preeclampsia.
    Jain M; Sawhney H; Aggarwal N; Vashistha K; Majumdhar S
    J Obstet Gynaecol Res; 2004 Jun; 30(3):188-92. PubMed ID: 15210040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
    Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
    Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.
    Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P
    Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
    Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
    Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
    Geiss HC; Otto C; Parhofer KG
    Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet's disease.
    Orem A; Cimşit G; Değer O; Vanizor B; Karahan SC
    Dermatology; 1999; 198(3):243-6. PubMed ID: 10393445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters--A comparison of two different apheresis techniques.
    Kopprasch S; Bornstein SR; Bergmann S; Graessler J; Julius U
    Atheroscler Suppl; 2015 May; 18():80-4. PubMed ID: 25936309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population.
    Chen HW; Kuo CL; Huang CS; Kuo SJ; Liu CS
    Cardiology; 2008; 110(4):252-9. PubMed ID: 18073481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies against low-density lipoprotein and atherogenic potential of blood.
    Kacharava AG; Tertov VV; Orekhov AN
    Ann Med; 1993 Dec; 25(6):551-5. PubMed ID: 8292305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between serum levels of autoantibodies against oxidized low density lipoproteins, lipid-soluble antioxidants and apolipoprotein B in patients with coronary heart disease.
    Bakalova RA; Hadzhimitova V; Ribarov S
    Gen Physiol Biophys; 2000 Mar; 19(1):103-13. PubMed ID: 10930142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.
    Ayyobi AF; McGladdery SH; McNeely MJ; Austin MA; Motulsky AG; Brunzell JD
    Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1289-94. PubMed ID: 12750118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significantly higher levels of oxidized LDL autoantibody in coronary artery disease patients.
    Liang KW; Huang JL; Kao CH; Hsueh CW; Ho HY; Lee WL; Wang KY; Huang DS; Chen YT; Ting CT
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):101-6. PubMed ID: 10677919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.